NCI-2022-04465

A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

This is a combined Phase 1/2 research study testing a new oral drug, BDTX-1535. This drug targets and blocks the Epidermal Growth Factor Receptor (EGFR) protein. EGFR is involved in cell growth and division, and mutations or overactivity of EGFR can contribute to cancer development. EGFR inhibitors are designed to stop cancer cells from growing by blocking this protein.The study is enrolling patients with either glioblastoma (a brain cancer) or non-small cell lung cancer. The primary goals are to determine a safe and effective dose of BDTX-1535, to assess how the body handles the drug, and to see if the drug shows any signs of effectiveness against these two types of cancer.

Phase 1/2: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05256290

Clinical Trial Site: Columbia

To see all available clinical trials click here.